ESC 2018 | ART: Disappointment with Bilateral Internal-Thoracic Artery Grafts After a 10-Year Follow-Up

Published 5-year results had been neutral for bilateral vs. single internal-thoracic artery grafts, but, at the time, surgeons argued that the time period analyzed was not enough and that a difference would be observed after 10 years of follow-up, once the trial finished. Such follow-up was presented at the European Society of Cardiology (ESC) Congress 2018 and the disappointment was big: bilateral internal-thoracic artery grafts offer no advantage.

ART: desilusión de la revascularización con doble mamaria a 10 años de seguimientoAfter a decade of follow-up, there was no difference between patients who underwent myocardial revascularization surgery involving two bilateral internal-thoracic artery grafts and those with a single arterial graft, plus vein or radial artery grafts, as regards a composite endpoint of death, infarction, and stroke.

 

No differences were observed either as regards major bleeding or repeat revascularization, although patients who received bilateral internal-thoracic artery grafts experienced more infections.

 

The study faced difficulties from the beginning. In fact, 36% of patients received a different strategy than that to which they had originally been randomized. A full 14% of patients randomized to bilateral internal-thoracic artery graft finally received a single internal-thoracic artery graft, while 22% of patients randomized to a single internal-thoracic artery graft received a second arterial graft, generally a radial artery graft.


Read also: ESC 2018 | CULPRIT-SHOCK: 1-Year Results Continue to Support Treatment of the Culprit Artery Only.


The use of medical treatment was one of the highlights, ranging from 73% to 89%, following clinical practice guidelines (which include aspirin, statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers).

 

The primary endpoint, a composite of death, infarction, and stroke, showed no differences between groups (hazard ratio [HR]: 0.90; 95% confidence interval [CI]: 0.78-1.03). Survival curves were nearly juxtaposed throughout the study.


Read also: ESC 2018 | MATRIX: 1-Year Superiority of Transradial Access.


There are several explanations for this disappointment: one might obviously be a lack of difference between these strategies, although there might be other factors involved. High adherence to medical treatment (a novelty, quite higher than rates observed in all other works comparing surgery and angioplasty, for example) may have diluted the expected differences in reintervention. The use of radial artery grafts in the single internal-thoracic artery graft group also may have influenced reinterventions (radial artery grafts proved to be superior to vein grafts), as well as the observed crossover rate, which may have played a part in the results.

 

Original title: Randomized Comparison of Single Versus Bilateral Internal Thoracic Artery Grafts in 3102 CABG Patients: Major Cardiovascular Outcomes at Ten Years of Follow Up.

Presenter: Taggart DP.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....